Akston Biosciences
  • Programs
    • Pipeline
    • Platform
    • Process
  • Company
    • Overview
    • Leadership
    • Facilities
    • Partners
    • Contact
  • Careers
    • Overview
    • Career Opportunities
    • Our Culture
    • Contact
  • News
    • Overview
    • In The News
    • Press Releases
    • Papers

Press Releases

8 February 2022

Akston Biosciences Announces Publication in Vaccine of Positive Data forĀ a Room Temperature Protein Subunit COVID-19 Vaccine

21 December 2021

Akston Biosciences Announces Positive Top-Line Data from Phase II Study of COVID-19 Vaccine in the NetherlandsĀ 

19 November 2021

Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine

9 February 2021

Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

5 August 2021

Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine

21 July 2021

Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-stable COVID-19 Vaccine at Global Scale

8 July 2021

Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

12 April 2021

Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

9 February 2021

Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

5 January 2021

Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452

Posts navigation

« 1 2 3 4 »

Akston BioSciences

info@akstonbio.com |

  • Home
  • Company
  • Pipeline
  • Careers
  • Press Releases
  • Contact

©2023 Akston Biosciences Corporation